India’s First Indigenous Tumour Antigen SPAG9- ASPAGNIITM

Cancer is one of the leading causes of death worldwide. ASPAGNIITM is an extraordinary breakthrough and innovation in treating this deadly disease. It is rightly in tune with the Atmanirbhar Bharat spirit. It is an affordable and indigenous product for cancer treatment.

Previously ASPAGNIITM is used in Dendritic Cell (DC) based immunotherapy in ovarian, cervical cancer and now will be used in treating breast cancer. It can revolutionize cancer treatment in India and the world. 

Background:

The researchers at the New Delhi-based National Institute of Immunology (NII), an Autonomous Institute of the Department of Biotechnology (DBT), and the clinicians at Cancer Institute, Adyar, Chennai, have been working together to discover a good treatment for cancer patients.

ASPAGNIITM:

Indias first indigenous tumor antigen, SPAG9 was discovered, by Dr. Anil Suri (head of the Cancer Research Program at NII) in 1998. Recently, the SPAG9 antigen has received the trademark ASPAGNIITM.

Statistics:

  • Every year Cancer kills 8.51 lakh people in India, as per International Agency for Research on Cancer, 2020, Globocan.
  • World Health Organization (WHO) report says 1 in 10 Indians develop cancer in their lifetime, and 1 in 15 will die of cancer.
  • By 2040, the number of new cancer cases worldwide per year can rise to 29.5 million and the number of cancer-related deaths to 16.4 million.

In Detail:

Immunotherapy is a new approach that exploits the inner capability of the body to fight against deadly cancer. Based on this approach, either the immune system of the people is given a boost, or the T-cells are trained to identify intractable cancer cells and kill them. Patients with SPAG9 protein get treated with a Dendritic Cell-based vaccine approach. In the Dendritic Cell-based vaccine, the cells called monocytes are collected from the blood of the patient and then modified into what is called dendritic cells. These dendritic cells are primed with ASPAGNIITMand are injected back into the patient’s body to help the fighter cells, or T-cells, present in the body to kill the cancer cells. Dendritic Cell-based immunotherapy is regarded as safe, affordable and can also promote antitumor immune responses and prolonged survival of cancer patients.

archanasabba

Writer, entrepreneur, runner, foodie, singer, dancer, yoga teacher, photographer, artist, adventurer.

View Comments

Recent Posts

Understanding the Rise in Suicide Rates

Suicide, the irreversible act of ending one's own life, is a deeply distressing phenomenon that…

10 months ago

XPoSat: Bridging Gaps in Astronomical Understanding Through Polarimetry and Spectroscopy

X-ray Polarimeter Satellite (XPoSat) XPoSat (X-ray Polarimeter Satellite) marks India’s first dedicated polarimetry mission exclusively…

11 months ago

LAUNCH OF MISSILE CUM AMMUNITION (MCA) BARGE, LSAM 10 (YARD 78) FOR INDIAN NAVY

On November 20, 2023, the fourth barge of the 08 x Missile Cum Ammunition Barge…

1 year ago

VAJRA PRAHAR 2023: Indo-US Special Forces Strengthening Bonds in Meghalaya

The 14th edition of the Indo-US Joint Special Forces exercise "VAJRA PRAHAR 2023" has commenced…

1 year ago

National Medical Devices Policy, 2023

The medical devices sector in India holds a crucial position within the nation's healthcare industry,…

1 year ago

National Quantum Mission to scale up scientific & industrial R&D for quantum technologies

The Union Cabinet, chaired by Hon'ble Prime Minister Shri Narendra Modi, has given its approval…

1 year ago